GPS2 and medulloblastoma: Among others, mutation of the GPS2 (G-protein Pathway Suppressor 2) gene was identified as a potential driver in both settings, in agreement with similar observations reported from genomic profiling of other cancer cohorts, including pan-cancer metastatic solid tumors (Priestley et al., 2019) and medulloblastomas (Pugh et al., 2012).